Overview

A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease

Status:
Terminated

Trial end date:
2020-07-22

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, three-arm, parallel-group, double-blind, placebo-controlled, study to evaluate the efficacy, safety and pharmacokinetics (PK) of pridopidine vs. placebo for the treatment of Levodopa Induced Dyskinesia (LID) in patients with Parkinson Disease.

Phase:

Phase 2

Details

Lead Sponsor:

Prilenia
Prilenia Therapeutics Development Ltd.

Treatments:

Levodopa